Archives of Medical Research
Volume 41, Issue 2 , Pages 110-118.e2 , February 2010

Gene Expression Profiling Identifies WNT7A As a Possible Candidate Gene for Decreased Cancer Risk in Fragile X Syndrome Patients

  • Mónica Alejandra Rosales-Reynoso

      Affiliations

    • División de Medicina Molecular, CIBO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
    • ,
  • Alejandra Berenice Ochoa-Hernández

      Affiliations

    • División de Genética, CIBO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
    • ,
  • Adriana Aguilar-Lemarroy

      Affiliations

    • División de Inmunología, CIBO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
    • ,
  • Luis Felipe Jave-Suárez

      Affiliations

    • División de Inmunología, CIBO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
    • ,
  • Rogelio Troyo-Sanromán

      Affiliations

    • Departamento de Fisiología, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, México
    • ,
  • Patricio Barros-Núñez

      Affiliations

    • División de Genética, CIBO, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
    • Corresponding Author InformationAddress reprint requests to: Dr. Patricio Barros-Núñez, División de Genética, AP 1-3838, Centro de Investigación Biomédica de Occidente, IMSS, Sierra Mojada 800, Col. Independencia, CP 44340, Guadalajara, Jalisco, México; Phone: (+52) (33) 3668-3000 ext. 31930

Received 19 September 2009 ,Accepted 25 January 2010.

References 

  1. Howard-Peebles P, Maddalena A, Black S, et al. Population screening for fragile X syndrome. Lancet. 1993;341:770
  2. Warren S, Sherman S. The fragile X syndrome. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic Basis of Inherited Disease. 7th edn. New York: McGraw-Hill; 2001;p. 1257–1289
  3. Lisik M, Sieron A. X-linked mental retardation. Med Sci Monit. 2008;14:RA221–229
  4. Bell M, Hirts M, Nakahori Y, et al. Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell. 1991;64:861–866
  5. Nolin S, Lewis F, Ye L, et al. Familial transmission of the FMR1 CGG repeat. Am J Hum Genet. 1996;59:1252–1261
  6. Bourgeois J, Coffey S, Rivera S, et al. Fragile X permutation disorders-expanding the psychiatric perspective. J Clin Psychiatry. 2009;70:852–862
  7. Durkin S, Glover T. Chromosome fragile sites. Annu Rev Genet. 2007;41:169–192
  8. Le Beau M. Chromosomal fragile sites and cancer-specific rearrangements. Blood. 1986;67:849–858
  9. Panzer S, Kuhl D, Caskey C. Unstable triplet repeat sequences: a source of cancer mutations. Stem Cells. 1995;13:146–157
  10. Del Pozo B, Millard P. Demonstration of the fra(X) in lymphocytes, fibroblasts, and bone marrow in a patient with a testicular tumor. J Med Genet. 1982;20:225–227
  11. Phelan M, Stevenson R, Collins J, et al. Fragile X syndrome and neoplasia. Am J Med Genet. 1988;30:77–82
  12. Rodewald L, Miller D, Sciorra L, et al. Brief clinical report: central nervous system neoplasm in a young man with Martin Bell syndrome-fra (X)–XLMR. Am J Med Genet. 1987;26:7–12
  13. Cunningham B, Dickerman J. Fragile X syndrome and acute lymphoblastic leukaemia. Cancer. 1988;62:2383–2386
  14. Au W, Man C, Pang A, et al. Acute lymphoblastic leukemia in a patient with fragile X syndrome. Haematologica. 2003;88:ECR13
  15. Shabtai F, Hart J, Klar D, et al. Fragile X expression in Martin-Bell syndrome, intellectually normal individuals, and neoplasia, interpreted by a viral hypothesis. Am J Med Genet. 1988;30:697–702
  16. Drouin V, Vannier J, Moirot H, et al. Nephroblastoma and fragile X syndrome. Arch Fr Pediatr. 1992;49:477
  17. Vorts E, Levene N, Nisani R, et al. Fragile X syndrome and myelodysplasia discovered during pregnancy. Br J Haematol. 1993;85:415–416
  18. de Graaff E, Willensem R, Zhong N, et al. Instability of the CGG repeat and expression of the FMR1 protein in a male fragile X patient with a lung tumor. Am J Hum Genet. 1995;57:609–618
  19. Fulchinogni-Lataud M, Olchwang S, Serre J. The fragile X CGG repeats show a marked level of instability in hereditary non-polyposis colorectal cancer patients. Eur J Hum Genet. 1997;5:89–93
  20. Ferrari A, Meazza C, Casanova M. Nasopharyngeal carcinoma in a boy with fragile X syndrome. Pediatr Hematol Oncol. 2000;17:597–600
  21. Kalkunte R, Macarthur D, Morton R. Glioblastoma in boy with fragile X: an unusual case of neuroprotection. Arch Dis Child. 2007;92:795–796
  22. Wirojanan J, Kraff J, Hawkins D, et al. Two boys with fragile X syndrome and hepatic tumors. J Pediatr Hematol Oncol. 2008;30:239–241
  23. Schultz-Pedersen S, Hasle H, Olsen H, et al. Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet. 2001;103:226–230
  24. Sund R, Pukkala E, Patja K. Cancer incidence among persons with fragile X syndrome in Finland: a population based study. J Intellect Disabil Res. 2009;53:85–90
  25. Hecht F, Ramesh K, Lockwood D. A guide to fragile sites on human chromosomes. Cancer Genet Cytogenet. 1990;44:37–45
  26. Sorensen S, Fenger K, Olsen J. Significantly lower incidence of cancer among patients with Huntington disease. Cancer. 1999;86:1342–1346
  27. Hasle H, Clemmensen I, Mikkelsen M. Risk of leukaemia and solid tumors in individuals with Down's syndrome. Lancet. 2000;355:165–169
  28. Li X, Jin P. Macro role(s) of microRNAs in fragile X syndrome. Neuromolecular Med. 2009;(Epub ahead of print)
  29. Siu Y, Jin D. CREBa real culprit in oncogenesis. FEBS J. 2007;274:3224–3232
  30. Al-wadei H, Schuller H. Cyclic adenosine monophosphate-dependent cell type specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells. Cancer Detect Prev. 2006;30:403–411
  31. Smith K, Nicholls R, Reines D. The gene encoding the fragile X RNA binding protein is controlled by nuclear respiratory factor 2 and CREB family of transcription factors. Nucleic Acids Res. 2006;34:1205–1215
  32. Hu H, Qin Y, Bochorishvili G. Ras signaling mechanisms underlaying impaired GluR1 dependent plasticity associated with fragile X syndrome. J Neurosci. 2008;28:7847–7862
  33. Govek E, Newey S, Van A. The role of the Rho GTPases in neuronal development. Genes Dev. 2005;19:1–49
  34. Schubbert S, Bollag G, Shannon K. Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Curr Opin Genet Dev. 2007;17:15–22
  35. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1214
  36. Panagopoulos I, Lassen C, Kristoffersson U, et al. Methylation PCR approach for detection of fragile X syndrome. Hum Mut. 1999;14:71–79
  37. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 2006;34:D354–357
  38. Kurochkin I, Yonemitsu N, Funahashi S, et al. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. Biochem Biophys Res Commun. 2001;280:340–347
  39. Smith C, McClive P, Sinclair A. Temporal and spatial expression profile of the novel armadillo-related gene, Alex 2, during testicular differentiation in the mouse embryo. Dev Dyn. 2005;233:188–193
  40. Deichmann M, Polychronidis M, Nackers J, et al. The protein phosphatase 2A subunit Bgamma gene is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Res. 2001;6:577–585
  41. Li H, Cai X, Shouse G, et al. A specific PP2A regulatory subunit, B56 gamma mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J. 2007;26:402–411
  42. Kirikoshi H, Katoh M. Expression of Wnt7a in human normal tissues and cancer, and regulation of Wnt7a and Wnt7b in human cancer. Int J Cancer. 2002;21:895–900
  43. Laggerbauer B, Ostareck D, Keidel E, et al. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet. 2001;10:329–338
  44. Jin P, Zarnescu D, Ceman S, et al. Biochemical and genetic interaction between the Fragile X mental retardation protein and the microRNA's pathway. Nat Neurosci. 2004;7:113–117
  45. Jin P, Alisch R, Warren S. RNA and microRNA's in fragile X mental retardation protein. Nat Cell Biol. 2004;6:1048–1053
  46. O'Donnell W, Warren S. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci. 2002;25:315–338
  47. Bagni C, Greenough W. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005;6:376–387
  48. Li Y, Lin L, Jin P. The microRNA pathway and Fragile X mental retardation protein. Biochim Biophys Acta. 2008;1779:702–705
  49. Brown V, Jin P, Ceman S, et al. Microarray identification of FMRP associated brain mRNAs and altered mRNA translational profiles in Fragile X Syndrome. Cell. 2001;107:477–487
  50. Bittel D, Kibiryeva N, Butler M. Whole genome microarray analysis of gene expression in subjects with fragile X syndrome. Genet Med. 2007;9:464–472
  51. Caricasole A, Ferraro T, Iacovelli L, et al. Functional characterization of WNT7A signaling in PC12 cells. J Biol Chem. 2003;39:37024–37031
  52. Carmon K, Loose D. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res. 2008;6:1017–1028
  53. Memarian A, Tehrani J, Vossough P, et al. Expression profile of Wnt molecules in leukemic cells from Iranian patients with acute myeloblastic leukemia. Iran J Immunol. 2007;3:145–154
  54. Khan N, Bendall L. Role of Wnt signaling in normal and malignant hematopoiesis. Histol Histopathol. 2006;21:761–774
  55. Oishi I, Suzuki H, Onishi N, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells. 2003;8:645–654
  56. Mikels A, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006;4:570–582
  57. Dosen G, Tenstad E, Nygren MK, et al. Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis. BMC Immunol. 2006;29:13–29
  58. Winn R, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005;20:19625–19634
  59. Lindberg D, Akerstrom G, Westin G. Mutational analyses of Wnt7a and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol. 2007;66:110–114
  60. Gaetje R, Holtrich U, Karn T, et al. Characterization of Wnt7a expression in human endometrium and endometriotic lesions. Fertil Steril. 2007;6:1534–1540

PII: S0188-4409(10)00026-3

doi: 10.1016/j.arcmed.2010.03.001

Archives of Medical Research
Volume 41, Issue 2 , Pages 110-118.e2 , February 2010

Article Tools

* Image Usage & Resolution